PATH | VRL
Menu

The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease

This article, published in Clinical and Vaccine Immunology, presents findings from a Phase 2b challenge study of an oral, live attenuated, three-strain recombinant bacterial vaccine, ACE527, against enterotoxigenic Escherichia coli (ETEC). Fifty-six of 70 human volunteers were challenged 28 days after the second dose of vaccine with the highly virulent ETEC strain H10407 to obtain preliminary indicators of efficacy against disease and to support further development of the vaccine for both travelers and infants in countries where ETEC is endemic. The vaccine had a significant impact on intestinal colonization by the challenge strain, and the incidence and severity of diarrhea were also reduced in vaccinees. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Darsley MJ, Chakraborty S, DeNearing B, et al.

Published: 2012

» Visit web page (English)

(Located at cvi.asm.org)

Citation: Darsley MJ, Chakraborty S, DeNearing B, et al. The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease. Clinical and Vaccine Immunology. 2012;19(12):1921-1931.

Resource types: Peer-reviewed journal

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Disease/vaccine specific information

Regions: Global